Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Equity Ratio (2016 - 2026)

Dexcom has reported Equity Ratio over the past 17 years, most recently at 0.45 for Q1 2026.

  • Quarterly Equity Ratio rose 32.78% to 0.45 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.45 through Mar 2026, up 32.78% year-over-year, with the annual reading at 0.43 for FY2025, 33.58% up from the prior year.
  • Equity Ratio was 0.45 for Q1 2026 at Dexcom, up from 0.43 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.45 in Q1 2026 and troughed at 0.31 in Q2 2023.
  • The 5-year median for Equity Ratio is 0.36 (2024), against an average of 0.37.
  • Year-over-year, Equity Ratio fell 28.78% in 2023 and then skyrocketed 33.58% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.4 in 2022, then decreased by 16.48% to 0.33 in 2023, then decreased by 1.8% to 0.32 in 2024, then skyrocketed by 33.58% to 0.43 in 2025, then grew by 2.92% to 0.45 in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Equity Ratio are 0.45 (Q1 2026), 0.43 (Q4 2025), and 0.36 (Q3 2025).